Literature DB >> 2553409

In vivo studies on the function of cardiac beta-adrenoceptors in man.

D G McDevitt1.   

Abstract

The original Lands classification considered cardiac beta-adrenoceptors to be predominantly beta 1 in type and to respond to both noradrenaline and adrenaline. Radioligand binding studies subsequently identified substantial numbers of beta 2-adrenoceptors in cardiac tissue. Studies in man employing intensive exercise, isoprenaline testing and a variety of selective and non-selective beta-adrenoceptor antagonists would now suggest that under certain circumstances these receptors may be functionally active. Severe exercise, as a sympathetic stimulus, is associated with high circulating noradrenaline concentrations, and appears to produce tachycardia predominantly by cardiac beta 1-adrenoceptor activity. In contrast, isoprenaline testing increases heart rate by a number of mechanisms: it stimulates beta 1-adrenoceptor activity in the sinoatrial node; it may result in reflex vagal withdrawal; and it appears to stimulate cardiac beta 2-adrenoceptors directly. In addition, isoprenaline also facilitates noradrenaline release by presynaptic beta 2-adrenoceptors. Thus the effects of isoprenaline would appear to mimic stress in man with the subsequent release of adrenaline from the adrenal medulla and its complex interaction directly and indirectly with both cardiac beta 1 and beta 2-adrenoceptors. These differing circumstances may also influence the relative efficacy of beta 1-selective and non-selective beta-adrenoceptor agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553409     DOI: 10.1093/eurheartj/10.suppl_b.22

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  14 in total

Review 1.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

2.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Beta-adrenoceptor density on mononuclear leukocytes and right atrial myocardium in infants and children with congenital heart disease.

Authors:  R Kozlik; H H Kramer; H Wicht; W Bircks; D Reinhardt
Journal:  Klin Wochenschr       Date:  1991-12-11

4.  The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

5.  Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.

Authors:  T Kaila; E Iisalo; A Lehtonen; H Saarimaa
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

6.  Zebrafish heart as a model to study the integrative autonomic control of pacemaker function.

Authors:  Matthew R Stoyek; T Alexander Quinn; Roger P Croll; Frank M Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-06-24       Impact factor: 4.733

7.  GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.

Authors:  Daniel Kurnik; Andrew J Cunningham; Gbenga G Sofowora; Utkarsh Kohli; Chun Li; Eitan A Friedman; Mordechai Muszkat; Usha B Menon; Alastair Jj Wood; C Michael Stein
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

8.  Regional distribution of beta 1- and beta 2-adrenoceptors in the failing and nonfailing human heart.

Authors:  M Steinfath; J Lavicky; W Schmitz; H Scholz; V Döring; P Kalmár
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.

Authors:  Daniel Kurnik; Chun Li; Gbenga G Sofowora; Eitan A Friedman; Mordechai Muszkat; Hong-Guang Xie; Paul A Harris; Scott M Williams; Usha B Nair; Alastair J J Wood; C Michael Stein
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

10.  Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response.

Authors:  Utkarsh Kohli; Britney L Grayson; Thomas M Aune; Laxmi V Ghimire; Daniel Kurnik; C Michael Stein
Journal:  Arch Drug Inf       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.